Etiology, Epidemiology and Treatment of Diarrhea and Enterocolitis in Hemato-oncological High Risk Patients (EpiDi)

Etiology, Epidemiology and Treatment of Diarrhea and Enterocolitis in Hemato-oncological High Risk Patients (EpiDi) - EpiDi

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000111

Enrollment

400

Registered

2009-06-16

Start date

2009-06-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematologic malignancy

Interventions

Group 1: No intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Neutropenia >= 5 days, defined as <500 neutrophils/microL. If no differential blood count available, use <1000 leukocytes/microL

Exclusion criteria

Exclusion criteria: a) Neutropenia <5 days, defined as <500 neutrophils/microL. If no differential blood count available, use <1000 leukocytes/microL b) Patients with Colitis ulcerosa, Morbus Crohn or other inflammatory diseases of the colon c) Patients with diarrhea at admission d) Patienten, receiving prophylaxis with metronidazole (per os or intravenous) or vancomycin (per os)

Design outcomes

Primary

Measure	Time frame
Incidence of abdominal complications after chemotherapy	—

Secondary

Measure	Time frame
Effect of empiric metronidazole or vancomycin on the incidence of abdominal complications	—

Countries

Germany

Contacts

Public ContactMaria J.G.T. Rüping

Uniklinik Köln, Klinik I für Innere Medizin, Studienzentrum 2 für Infektiologie

maria.rueping@ctuc.de+49 221 478 6494

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026